Clinical and laboratory characterization of patients with localized scleroderma and response to UVA‐1 phototherapy: In vivo and in vitro skin models
L Tognetti, C Marrocco, A Carraro… - Photodermatology …, 2022 - Wiley Online Library
Abstract Background/Purpose Localized scleroderma (LS) is a rare disease leading to
progressive hardening and induration of the skin and subcutaneous tissues. LS is …
progressive hardening and induration of the skin and subcutaneous tissues. LS is …
[引用][C] Targeted Medium Dose UVA-1 Phototherapy for the Treatment of Localized Scleroderma in the Skin of Color: Pros and Cons
S Shalaby, M Bosseila, M Fawzy, DMA Halim - WJMS, 2015
Therapeutic approaches to systemic sclerosis: recent approvals and future candidate therapies
A Lescoat, D Roofeh, M Kuwana, R Lafyatis… - Clinical reviews in …, 2023 - Springer
Systemic sclerosis is the rheumatic disease with the highest individual mortality. The severity
of the disease is determined by the extent of fibrotic changes to cutaneous and internal …
of the disease is determined by the extent of fibrotic changes to cutaneous and internal …
Low-dose UVA1 Phototherapy for Localized Scleroderma
NH YOUN, DO YOO, SH CHA… - Korean Journal of …, 2002 - pesquisa.bvsalud.org
Localized scleroderma (LS) is sclerosis of the skin characterized by one or multiple
circumscribed ivory-white, indurated, sometimes confluent plaques. It has been reported that …
circumscribed ivory-white, indurated, sometimes confluent plaques. It has been reported that …
A New Treatment Modality of Localized Scleroderma: Low-Dose UVA1 Phototherapy
T Dirschka, G von Kobyletzki, M Freitag… - Skin Cancer and UV …, 1996 - Springer
Localized Scleroderma (LS) is a chronically inflammatory skin disease leading to increasing
fibrosis of circumscribed areas of the skin. Various treatment modalities, including those with …
fibrosis of circumscribed areas of the skin. Various treatment modalities, including those with …
Association of skin hyperpigmentation disorders with digital ulcers in systemic sclerosis: analysis of a cohort of 239 patients
Background Skin pigmentation disorders in systemic sclerosis (SSc) have been sparsely
described in the literature. Nevertheless, they could be a diagnostic and/or severity marker …
described in the literature. Nevertheless, they could be a diagnostic and/or severity marker …
Scleroderma Skin: How Is Treatment Best Guided by Data and Implemented in Clinical Practice?
Skin involvement is the hallmark and most clinically evident aspect of systemic sclerosis
(SSc). 1 Even the disease name is derived from skin involvement;“scleroderma” originates …
(SSc). 1 Even the disease name is derived from skin involvement;“scleroderma” originates …
Low-dose UVA1 phototherapy in systemic sclerosis: effects on acrosclerosis
A Kreuter, F Breuckmann, A Uhle, N Brockmeyer… - Journal of the American …, 2004 - Elsevier
BACKGROUND: Increased collagen synthesis, vascular damage, and T-lymphocytic
infiltration contribute to the development of systemic sclerosis. Preliminary studies revealed …
infiltration contribute to the development of systemic sclerosis. Preliminary studies revealed …
Suggested mechanisms of action of UVA phototherapy in morphea: a molecular study
M El‐Mofty, W Mostafa, S Esmat… - Photodermatology …, 2004 - Wiley Online Library
Background: Ultraviolet A (UVA) phototherapy proved to be an efficient line of treatment of
scleroderma. The mechanism through which it acts is still not clear. Objective: To detect the …
scleroderma. The mechanism through which it acts is still not clear. Objective: To detect the …
Evaluation of medium-dose UVA1 phototherapy in localized scleroderma with the cutometer and fast Fourier transform method
MA De Rie, DNH Enomoto, HJC De Vries, JD Bos - Dermatology, 2003 - karger.com
Purpose: To evaluate the efficacy of medium-dose UVA1 phototherapy in patients with
localized scleroderma. Method: A controlled pilot study with medium-dose UVA1 (48 J/cm2) …
localized scleroderma. Method: A controlled pilot study with medium-dose UVA1 (48 J/cm2) …